title: A Murine Orthotopic Bladder Tumor Model and Tumor Detection System.
abstract: This protocol describes the generation of bladder tumors in female C57BL/6J mice using the murine bladder cancer cell line MB49, which has been modified to secrete human Prostate Specific Antigen (PSA), and the procedure for the confirmation of tumor implantation. In brief, mice are anesthetized using injectable drugs and are made to lay in the dorsal position. Urine is vacated from the bladder and 50 µL of poly-L-lysine (PLL) is slowly instilled at a rate of 10 µL/20 s using a 24 G IV catheter. It is left in the bladder for 20 min by stoppering the catheter. The catheter is removed and PLL is vacated by gentle pressure on the bladder. This is followed by instillation of the murine bladder cancer cell line (1 x 105cells/50 µL) at a rate of 10 µL/20 s. The catheter is stoppered to prevent premature evacuation. After 1 h, the mice are revived with a reversal drug, and the bladder is vacated. The slow instillation rate is important, as it reduces vesico-ureteral reflux, which can cause tumors to occur in the upper urinary tract and in the kidneys. The cell line should be well re-suspended to reduce clumping of cells, as this can lead to uneven tumor sizes after implantation. This technique induces tumors with high efficiency. Tumor growth is monitored by urinary PSA secretion. PSA marker monitoring is more reliable than ultrasound or fluorescence imaging for the detection of the presence of tumors in the bladder. Tumors in mice generally reach a maximum size that negatively impacts health by about 3 - 4 weeks if left untreated. By monitoring tumor growth, it is possible to differentiate mice that were cured from those that were not successfully implanted with tumors. With only end-point analysis, the latter may be mistakenly assumed to have been cured by therapy.
authors.affiliation: Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System.
authors.forename: Sin Mun
authors.initials: SM
authors.lastname: Tham
authors.affiliation: Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System; Department of Urology, National University Hospital.
authors.forename: Kesavan
authors.initials: K
authors.lastname: Esuvaranathan
authors.affiliation: Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System; surrm@nus.edu.sg.
authors.forename: Ratha
authors.initials: R
authors.lastname: Mahendran
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007610:Kallikreins / Q000032:analysis*; D008239:Lysine / Q000008:administration & dosage; D051379:Mice; D008810:Mice, Inbred C57BL; D017430:Prostate-Specific Antigen / Q000032:analysis*; D001749:Urinary Bladder Neoplasms / Q000473:pathology*
chemical_list: C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen; D008239:Lysine